Heart transplantation (HT) and durable left ventricular assist device (LVAD) support are established surgical treatment options for patients with end-stage systolic heart failure (HF) and/or nonrecoverable cardiogenic shock. HT is currently considered the gold standard therapy, with reported median survival of approximately 10–13 years. However, its utility in the lifetime management of younger patients (under 50 years of age) is limited, given low rates of re-transplantation. With continued advancements in durable LVAD technology, median survival following LVAD implantation in younger patients now exceeds 7 years. In an era marked by increasing HF prevalence, persistent donor heart shortages, evolving organ allocation policies, growing concerns regarding equity of care, and progress in the cardiac function enhancement therapies, LVAD and HT should be considered synergistic rather than competing therapies in selected advanced HF populations. Specifically, the strategy of intentional LVAD implantation as a first-line approach in transplant-eligible younger adults and older adolescents might extend the therapeutic horizon and optimize lifetime management.